BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright

By Yahoo! Finance | 1 week ago

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotech company with high growth potential. Its success is driven by the uptake of the Attruby product for treating ATTR-CM. The company aims to provide innovative medications for hereditary disorders, making it a promising investment option.

Did you find this insightful?